Table 1.
MS patient demographics used in miRNA profiling, mRNA expression profiling, and RT‐qPCR validation study.
| Sample# | MS types | Age (years)/sex | PMI (h) | Disease duration (years) | EDSS | Lesion type | |
|---|---|---|---|---|---|---|---|
| 1 | SPMS | 65/F | 7 | 19 | 8 | NAGM | miRNAs profiling |
| 2 | SPMS | 53/F | 5 | 19 | 9 | NAGM | |
| 3 | SPMS | 52/M | 6 | 30 | 9 | NAGM | |
| 4 | PPMS | 63/M | 4 | 10 | 8 | NAGM | |
| 5 | PPMS | 57/F | 5 | 15 | 6.5 | NAGM | |
| 6 | PPMS | 62/F | 4 | 46 | 8 | GML | |
| 7 | SPMS | 46/F | 5 | 14 | 8 | GML | |
| 8 | SPMS | 66/F | 13 | 35 | 8 | GML | |
| 9 | SPMS | 59/F | 5 | 38 | 7 | GML | |
| 10 | SPMS | 48/F | 5 | 27 | 9 | GML | |
| 11 | SPMS | 45/M | 3 | 36 | 7 | NAGM, GML | mRNA expression profiling |
| 12 | SPMS | 60/F | 8 | 29 | 9 | NAGM, GML | |
| 13 | SPMS | 52/M | 5 | 25 | 9.5 | NAGM, GML | |
| 14 | PPMS | 63/F | 5 | 9 | 7.5 | GML | |
| 15 | SPMS | 53/F | 6 | 19 | 9 | NAGM, GML | |
| 16 | SPMS | 52/M | 7 | 30 | 9 | NAGM, GML | |
| 17 | SPMS | 97/F | 14 | 45 | 7.5 | NAGM, GML | |
| 18 | PPMS | 70/M | 10 | 17 | 6.5 | GML | |
| 19 | RRMS | 59/M | 9 | 10 | 8.5 | NAGM | RT‐qPCR validation |
| 20 | SPMS | 50/F | 9 | 17 | 8 | NAGM, GML | |
| 21 | SPMS | 77/F | 6 | 54 | 9 | NAGM | |
| 22 | SPMS | 61/M | 10 | 43 | 6.5 | NAGM | |
| 23 | SPMS | 67/M | 11 | 25 | 8 | GML | |
| 24 | PPMS | 70/F | 9 | 17 | 8 | GML | |
| 25 | PPMS | 69/F | 6 | 20 | 9 | GML |
Abbreviations: EDSS, Expanded Disability Status Scale; GML, gray matter lesion; NAGM, normal appearing gray matter; PMI, post mortem interval (h); PPMS, primary progressive MS; RRMS, Relapse remitting MS; SPMS, secondary progressive MS.